Kronos Bio Reports Recent Business Progress and Third Quarter 2020 Financial Results
Acquired from Gilead Sciences a portfolio of SYK inhibitors, including lead investigational therapy entospletinib being developed for frontline treatment of...
Acquired from Gilead Sciences a portfolio of SYK inhibitors, including lead investigational therapy entospletinib being developed for frontline treatment of...
* Significant short and long-term clinical improvement for a hospitalized patient with a rare disease that currently has no effective...
LOS ANGELES, Nov. 18, 2020 (GLOBE NEWSWIRE) -- via InvestorWire -- Tongji Healthcare Group, Inc. (OTCMKTS:TONJ) (“Tongji” or the “Company”)...
TORONTO, Nov. 18, 2020 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) is pleased to announce that...
REDWOOD CITY, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Carrot, a digital health company that delivers clinically proven, behavioral science-based...
NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Better Choice Company, Inc. (OTCQB: BTTR) (the “Company” or “Better Choice”), an...
New York City, Nov. 18, 2020 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB:...
The Company takes first step in its expansion with the addition of a 300,000 sq. ft. facility within Monterey County...
Primary efficacy analysis demonstrates BNT162b2 to be 95% effective against COVID-19 beginning 28 days after the first dose; 170 confirmed...
MORRISVILLE, N.C., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only...
TORONTO, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company...
TORONTO and HOUSTON, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA),...
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 18, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company...
91% of patients on MYCAPSSA maintained IGF-1 response in the 9-month randomized, controlled phase of the non-inferiority trial Company intends...
Findings further support the differentiated multifactorial mechanism of action of VASCEPA and its robust clinical effectiveness in reducing major adverse...
RESEARCH TRIANGLE PARK, N.C., Nov. 18, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today...
INCHEON, South Korea and CAMBRIDGE, Mass., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq:...
Kaken plans to launch ECCLOCK®for the treatment of primary axillary hyperhidrosis in Japan on November 26, 2020- - -ECCLOCK®placed on...
CRESSKILL, N.J. and JERUSALEM, Israel, Nov. 18, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the...
PLX-R18 demonstrated significant clinical improvements in Hb, ANC, and PLT among the high-dose cohort PLX-R18 was found to be safe...